Literature DB >> 23236176

Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin.

Yi Pu Lin1, Xiaoli Xiong, Stephen A Wharton, Stephen R Martin, Peter J Coombs, Sebastien G Vachieri, Evangelos Christodoulou, Philip A Walker, Junfeng Liu, John J Skehel, Steven J Gamblin, Alan J Hay, Rodney S Daniels, John W McCauley.   

Abstract

The hemagglutinin (HA) of influenza A(H3N2) virus responsible for the 1968 influenza pandemic derived from an avian virus. On introduction into humans, its receptor binding properties had changed from a preference for avian receptors (α2,3-linked sialic acid) to a preference for human receptors (α2,6-linked sialic acid). By 2001, the avidity of human H3 viruses for avian receptors had declined, and since then the affinity for human receptors has also decreased significantly. These changes in receptor binding, which correlate with increased difficulties in virus propagation in vitro and in antigenic analysis, have been assessed by virus hemagglutination of erythrocytes from different species and quantified by measuring virus binding to receptor analogs using surface biolayer interferometry. Crystal structures of HA-receptor analog complexes formed with HAs from viruses isolated in 2004 and 2005 reveal significant differences in the conformation of the 220-loop of HA1, relative to the 1968 structure, resulting in altered interactions between the HA and the receptor analog that explain the changes in receptor affinity. Site-specific mutagenesis shows the HA1 Asp-225→Asn substitution to be the key determinant of the decreased receptor binding in viruses circulating since 2005. Our results indicate that the evolution of human influenza A(H3N2) viruses since 1968 has produced a virus with a low propensity to bind human receptor analogs, and this loss of avidity correlates with the marked reduction in A(H3N2) virus disease impact in the last 10 y.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23236176      PMCID: PMC3535595          DOI: 10.1073/pnas.1218841110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Recommended composition of influenza vaccines for use in the 2012 southern hemisphere influenza season.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2011-10-14

2.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

3.  Optimal description of a protein structure in terms of multiple groups undergoing TLS motion.

Authors:  Jay Painter; Ethan A Merritt
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-03-18

4.  Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season.

Authors:  Ian G Barr; John McCauley; Nancy Cox; Rod Daniels; Othmar G Engelhardt; Keiji Fukuda; Gary Grohmann; Alan Hay; Anne Kelso; Alexander Klimov; Takato Odagiri; Derek Smith; Colin Russell; Masato Tashiro; Richard Webby; John Wood; Zhiping Ye; Wenqing Zhang
Journal:  Vaccine       Date:  2009-12-09       Impact factor: 3.641

5.  A DNA transfection system for generation of influenza A virus from eight plasmids.

Authors:  E Hoffmann; G Neumann; Y Kawaoka; G Hobom; R G Webster
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

6.  Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy.

Authors:  Suman R Das; Scott E Hensley; Alexandre David; Loren Schmidt; James S Gibbs; Pere Puigbò; William L Ince; Jack R Bennink; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

7.  Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides.

Authors:  E Nobusawa; H Ishihara; T Morishita; K Sato; K Nakajima
Journal:  Virology       Date:  2000-12-20       Impact factor: 3.616

8.  Hemagglutinin residues of recent human A(H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes.

Authors:  R Medeiros; N Escriou; N Naffakh; J C Manuguerra; S van der Werf
Journal:  Virology       Date:  2001-10-10       Impact factor: 3.616

9.  Dynamics of glycoprotein charge in the evolutionary history of human influenza.

Authors:  Nimalan Arinaminpathy; Bryan Grenfell
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

10.  The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies.

Authors:  P S Daniels; S Jeffries; P Yates; G C Schild; G N Rogers; J C Paulson; S A Wharton; A R Douglas; J J Skehel; D C Wiley
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

View more
  136 in total

1.  The effects of a deleterious mutation load on patterns of influenza A/H3N2's antigenic evolution in humans.

Authors:  Katia Koelle; David A Rasmussen
Journal:  Elife       Date:  2015-09-15       Impact factor: 8.140

2.  Phenotypic Effects of Substitutions within the Receptor Binding Site of Highly Pathogenic Avian Influenza H5N1 Virus Observed during Human Infection.

Authors:  Dirk Eggink; Monique Spronken; Roosmarijn van der Woude; Jocynthe Buzink; Frederik Broszeit; Ryan McBride; Hana A Pawestri; Vivi Setiawaty; James C Paulson; Geert-Jan Boons; Ron A M Fouchier; Colin A Russell; Menno D de Jong; Robert P de Vries
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

3.  The 150-Loop Restricts the Host Specificity of Human H10N8 Influenza Virus.

Authors:  Netanel Tzarum; Robert P de Vries; Wenjie Peng; Andrew J Thompson; Kim M Bouwman; Ryan McBride; Wenli Yu; Xueyong Zhu; Monique H Verheije; James C Paulson; Ian A Wilson
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

4.  Influenza: Pathways to human adaptation.

Authors:  David A Steinhauer
Journal:  Nature       Date:  2013-07-17       Impact factor: 49.962

5.  Diversity of Functionally Permissive Sequences in the Receptor-Binding Site of Influenza Hemagglutinin.

Authors:  Nicholas C Wu; Jia Xie; Tianqing Zheng; Corwin M Nycholat; Geramie Grande; James C Paulson; Richard A Lerner; Ian A Wilson
Journal:  Cell Host Microbe       Date:  2017-06-14       Impact factor: 21.023

6.  Neuraminidase-mediated haemagglutination of recent human influenza A(H3N2) viruses is determined by arginine 150 flanking the neuraminidase catalytic site.

Authors:  Ramona Mögling; Mathilde J Richard; Stefan van der Vliet; Ruud van Beek; Eefje J A Schrauwen; Monique I Spronken; Guus F Rimmelzwaan; Ron A M Fouchier
Journal:  J Gen Virol       Date:  2017-06-13       Impact factor: 3.891

7.  Adaptation of avian influenza A (H6N1) virus from avian to human receptor-binding preference.

Authors:  Fei Wang; Jianxun Qi; Yuhai Bi; Wei Zhang; Min Wang; Baorong Zhang; Ming Wang; Jinhua Liu; Jinghua Yan; Yi Shi; George F Gao
Journal:  EMBO J       Date:  2015-05-04       Impact factor: 11.598

8.  A human-infecting H10N8 influenza virus retains a strong preference for avian-type receptors.

Authors:  Heng Zhang; Robert P de Vries; Netanel Tzarum; Xueyong Zhu; Wenli Yu; Ryan McBride; James C Paulson; Ian A Wilson
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

9.  Structure and receptor binding of the hemagglutinin from a human H6N1 influenza virus.

Authors:  Netanel Tzarum; Robert P de Vries; Xueyong Zhu; Wenli Yu; Ryan McBride; James C Paulson; Ian A Wilson
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

10.  Receptor binding by a ferret-transmissible H5 avian influenza virus.

Authors:  Xiaoli Xiong; Peter J Coombs; Stephen R Martin; Junfeng Liu; Haixia Xiao; John W McCauley; Kathrin Locher; Philip A Walker; Patrick J Collins; Yoshihiro Kawaoka; John J Skehel; Steven J Gamblin
Journal:  Nature       Date:  2013-04-24       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.